NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies.
NurExone chose to base its ultimate drug delivery platform on exosomes-nanosized extracellular vesicles-due to their natural ability to reach inflamed or damaged tissue. By loading exosomes with therapeutic compounds, nanodrugs are created, having natural regenerative properties and therapeutic impact.
Here is a video detailing the tech.
I own some and am trying to understand why more investors don’t see the potential. And it’s not that I am trying to pump the stock; it will reward investors handsomely over time. It already has a 52-week range of CDN.1850 to CDN1.19. It’s a six-bagger.
Initial indications from a preclinical study have demonstrated the potential for an off-the-shelf therapy for non-invasive administration shortly after spinal cord trauma. The product, which would not require personalization, is expected to reduce damage from a spinal cord injury and to improve the chance of functional recovery.
NXR’s ExoTherapy platform is used to develop the first exosome-loaded nano-drug, ExoPTEN, for acute Spinal Cord Injuries (SCI), targeted at a global market projected at $2.9 billion. Partnerships and licensing of the ExoTherapy platform to the global biopharmaceutical industry targeting other diseases and indications.
I believe the Company is delving into Glaucoma treatment. At the same time, likely just the start of many afflictions that benefit from its delivery tech, it also brings more interest to a larger pool of investors. As with all biopharmaceuticals, there is that sweet spot where complex technology reaches out with a commonality it may have lacked.
In other words, people/investors see the clinical/investment potential.
Prof. Michael Belkin commented: “We are excited to perform preclinical studies on optical nerve regeneration at the Sheba Medical Center Eye Institute. If this experimental direction is successful, I believe we may be able to translate the success quickly to clinical practice. Our ultimate goal is to restore and improve the quality of life for individuals affected by optic nerve diseases and injuries.”
Here’s a list of resources;
Finally, Orphan Drug Status
Do not discount the importance of Orphan Drug status. It is a massive leap for NRX, and any drug company with this designation is worth watching.
Advantage Nurexone.
Bob Beaty
For over 30 years, Bob Beaty has been explaining concepts and companies to the global investment community. One of the original writers for Jim Cramer’s Thestreet.com, he also wrote for AOL (Can/US), the Globe and Mail, and the Huffington Post. Over that period, he illuminated small-cap companies to investors with wit and pith but mostly opinion and facts. Investing should be fun. Pedantic, staid content is no fun.
Before embarking on his writing career, Bob had a successful international journey in the finance industry. He served as a broker, derivatives product manager, and a Director of London's Credit Suisse subsidiary. His career spanned across major financial hubs including Toronto, Vancouver, and the UK, giving him a unique global perspective. (He is still fondly remembering those English client lunches.)
Other than everything Groucho Marx and George Carlin ever said, Bob lives by a simple credo;
‘Never do anything the person standing in front of you can't understand.’ Hunter S. Thompson.
Let’s go.
